← Back to Concord Biotech Ltd. overview
Concord Biotech Ltd. — 10-Year Financials
Annual P&L, balance sheet, and key ratios from public BSE/NSE filings.
| Period | Revenue | Net Profit | EPS (₹) | Total Assets | Shareholder Equity | ROE (%) | ROCE (%) | D/E | Net Margin (%) |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹1,180 cr | ₹372 cr | ₹35.52 | ₹2,034 cr | ₹1,813 cr | 20.5% | 27.27% | 0x | 31.5% |
| FY2024 | ₹998 cr | ₹308 cr | ₹29.45 | ₹1,701 cr | ₹1,527 cr | 20.18% | 27.02% | 0.01x | 30.87% |
| FY2023 | ₹831 cr | ₹240 cr | ₹22.95 | ₹1,514 cr | ₹1,290 cr | 18.61% | 24.71% | 0.02x | 28.9% |
| FY2022 | ₹708 cr | ₹175 cr | ₹16.72 | ₹1,313 cr | ₹1,103 cr | 15.86% | 20.85% | 0.06x | 24.69% |
Revenue: Total income from operations (₹ crore).
EPS: Earnings per share (₹), basic.
ROE: Net profit / average shareholder equity.
ROCE: EBIT / capital employed.
D/E: Total debt / shareholder equity.
Net Margin: Net profit as a % of revenue.
All figures sourced from public BSE/NSE filings. Ratios are pre-computed estimates and may differ from primary filings due to rounding.
Educational content — not investment adviceAll financial data is sourced from public filings and shown here for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing on this page constitutes a recommendation or solicitation to transact in any security. All data is at least 90 days old. Past performance is not indicative of future results.